Watermark
Watermark

Clinical Trials

We are committed to bringing innovative treatment options to patients worldwide.

We are recruiting for clinical trials across a wide range of therapeutic indications, including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.

Our company, previously known as BeiGene, is now officially BeOne Medicines.

Our new identity reflects who we are today: a united, purpose-driven, and globally focused oncology company. It underscores our deep commitment to advancing science, accelerating innovation, and delivering breakthrough therapies that change lives. BeOne Medicines embodies our belief that together—as one—we can redefine what’s possible in cancer care.

Because some of our older studies were sponsored under the name BeiGene, you may see both names used in our studies on this website.

 

Young woman embracing cancer patient in wheelchair

Questions about a clinical trial?

If you are a patient or a health care provider and would like more information about a clinical trial, please contact our research team.

Reach a BeOne Representative

Search Clinical Trials

For a more refined search, use the Advanced Search

  • Age
  • Available Documents
  • Patient Level Data Anonymized patient level data for select studies available to qualified scientific researchers
  • Phases Phase 1: A step in clinical research to focus on the safety of a drug and how it works in the body. Phase 2: A step in clinical research to gather data on whether a drug works in people who have a certain condition or disease. Phase 3: A step in clinical research that gathers more information about a drug’s safety and if it works in people. Phase 4: A step in clinical research after regulatory authorities have approved a drug for marketing. N/A: For observational studies or interventional studies that do not support drug development.
  • Results
  • Sex In this context, a person’s sex refers to that person’s assigned sex at birth. This has been the case historically; however, there is growing understanding in the healthcare community that this definition excludes certain segments of the population and should be expanded, where possible, to account for gender identity as well. BeiGene recognizes the importance of making clinical trials accessible to all groups of people and is committed to promoting inclusive research.
  • Statistical Analysis Plan: SAP for Primary Analysis CSR
  • Statistical Analysis Plan: SAP for Study Closeout Analysis CSR
  • Study Status Recruiting: The study is open to enrollment for qualified participants. Will be Recruiting: The study has not yet opened enrollment for qualified participants. Recruitment Complete: The study is ongoing, and participants are receiving an intervention or being examined, but new potential participants are not currently being recruited or enrolled. Completed: The study has ended normally, and participants are no longer receiving an intervention or being examined. Other: All other study statuses such as withdrawn, canceled, or terminated.
  • Study Type <strong>Expanded Access:</strong> A way for patients with serious diseases or conditions who cannot participate in a clinical study to gain access to a medical product that has not been approved by regulatory authorities. Also called compassionate use. <strong>Interventional:</strong> A type of clinical trial in which participants are assigned to groups that receive one or more treatment or study drug (intervention). <strong>Observational:</strong> A type of clinical study in which participants may receive diagnostic or study drugs but the study investigator does not assign participants to a a specific intervention or treatment.
Clear

Search Results

Study ID
Phase
Condition(s)
Status
Sex
Age Range
BGB-3111_GA101_Study_001
1

B-cell Lymphoid Malignancies

Completed

All

18 Years / N/A

Learn More
BGB-3111_GA101_Study_001

Completed

Phase

1

Condition

B-cell Lymphoid Malignancies

Sex

All

Age

18 Years / N/A

Learn More
BGB-900-102
1/2

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Completed

All

18 Years / N/A

Learn More
BGB-900-102

Completed

Phase

1/2

Condition

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Sex

All

Age

18 Years / N/A

Learn More
BGB-900-103
1

Advanced Solid Tumors

Completed

All

18 Years / N/A

Learn More
BGB-900-103

Completed

Phase

1

Condition

Advanced Solid Tumors

Sex

All

Age

18 Years / N/A

Learn More
BGB-900-104
1/2

Carcinoma, Hepatocellular

Completed

All

18 Years / N/A

Learn More
BGB-900-104

Completed

Phase

1/2

Condition

Carcinoma, Hepatocellular

Sex

All

Age

18 Years / N/A

Learn More
BGB-900-105
1

Locally Advanced and Metastatic Solid Tumors

Completed

All

18 Years / N/A

Learn More
BGB-900-105

Completed

Phase

1

Condition

Locally Advanced and Metastatic Solid Tumors

Sex

All

Age

18 Years / N/A

Learn More
BGB-A317-102
1/2

Advanced Solid Tumors

Completed

All

18 Years / N/A

Learn More
BGB-A317-102

Completed

Phase

1/2

Condition

Advanced Solid Tumors

Sex

All

Age

18 Years / N/A

Learn More
BGB-A317-203
2

Classical Hodgkin Lymphoma

Completed

All

18 Years / N/A

Learn More
BGB-A317-203

Completed

Phase

2

Condition

Classical Hodgkin Lymphoma

Sex

All

Age

18 Years / N/A

Learn More
BGB-A317-204
2

Locally Advanced or Metastatic Urothelial Bladder Cancer

Completed

All

18 Years / N/A

Learn More
BGB-A317-204

Completed

Phase

2

Condition

Locally Advanced or Metastatic Urothelial Bladder Cancer

Sex

All

Age

18 Years / N/A

Learn More
BGB-A317-205
2

Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

Completed

All

18 Years / 75 Years

Learn More
BGB-A317-205

Completed

Phase

2

Condition

Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

Sex

All

Age

18 Years / 75 Years

Learn More
BGB-A317-206
2

Locally Advanced Lung Cancer; Metastatic Lung Cancer

Completed

All

18 Years / 75 Years

Learn More
BGB-A317-206

Completed

Phase

2

Condition

Locally Advanced Lung Cancer; Metastatic Lung Cancer

Sex

All

Age

18 Years / 75 Years

Learn More